Source: DiaMedica Inc.

DiaMedica to Present at the 14th Annual BIO CEO and Investor Conference

WINNIPEG, MANITOBA--(Marketwire - Feb. 13, 2012) - DiaMedica Inc. (TSX VENTURE:DMA) a biopharmaceutical company focused on the development of novel treatments for Type 1 and Type 2 diabetes announced today that Mr. Rick Pauls, DiaMedica's President and Chief Executive Officer, will present at the 2012 BIO CEO & Investor Conference in New York on Monday, February 13, 2012 at 4:30 p.m. Eastern Time at the Waldorf-Astoria in New York City. At the conference, which is hosted by the Biotechnology Industry Organization (BIO), Mr. Pauls will provide an overview of DiaMedica's diabetes programs.

About BIO CEO & Investor Conference

The BIO CEO & Investor Conference is the largest independent investor conference focused on publicly-traded biotechnology companies. The conference provides a forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry through issue-oriented plenary sessions, educational sessions focused on hot therapeutic areas and key business issues, company presentations, and one-on-one meetings.

About DiaMedica

DiaMedica is a biopharmaceutical company focused on discovery and development of novel therapeutic compounds for diabetes and other major, medically-unmet diseases. DiaMedica's lead compound, DM-199, is a recombinant human protein that represents a novel approach to treating Type 1 and Type 2 diabetes. In a Type 1 diabetes model, DM-199 halted the autoimmune attack on beta cells by stimulating regulatory T-cells, and resulted in a 12-fold increase in C-peptide levels. In Type 2 diabetes models, DM-199 treatment stimulated proliferation of insulin producing beta cells and significant improvement in glucose control.

DiaMedica is also developing a novel monoclonal antibody, DM-204 as a treatment for Type 2 diabetes. Chronic treatment with DM-204 in a Type 2 diabetes model resulted in significant improvement in blood glucose control and HbA1c levels and also significant decreases in blood pressure and serum cholesterol.

Both DM-199 and DM-204 have proven efficacious in treating several other, non-diabetes related, disease models.

The company is listed on the TSX Venture Exchange under the trading symbol 'DMA'.

Caution Regarding Forward-Looking Information

The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address DiaMedica's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Company's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Company undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Contact Information:

DiaMedica Inc.
Rick Pauls
President & CEO
204.477.7590
204.453.3745 (FAX)
rpauls@diamedica.com